智通财经APP获悉，和铂医药-B(02142)涨超6%，高见4.15港元创2022年7月以来新高。值得一提的是，该股近期持续攀升，年内股价涨幅高达1.2倍。截至发稿，涨6.43%，报4.14港元，成交额1956.12万港元。
消息面上，和铂医药午间宣布，集团针对胸腺基质淋巴细胞生成素(TSLP)的全人源单克隆抗体HBM9378/SKB378(亦称为WIN378)已获得中国国家药品监督管理局(NMPA)药品审评中心的新药研究申请(IND)批件，以开展治疗慢性阻塞性肺病(COPD)的临床试验。据悉，HBM9378/SKB378是公司与科伦博泰开展的共同开发项目，二者共同享有大中华地区及多个东南亚及西亚国家的权利。
公司此前宣布，与科伦博泰就HBM9378/SKB378与Windward Bio签订许可协议。Windward Bio获得HBM9378/SKB378在全球范围内（不包括大中华区以及部分东南亚及西亚国家）进行研究、开发、生产和商业化的独家授权。授权方有权收取最多合共9.7亿美元预付款及里程碑付款以及占净销售额个位数到双位数百分比的分层特许权使用费。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.